- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01421251
H1N1 Vaccine Safety in Manitoba, Canada
The Safety of GSK Biological's H1N1 Pandemic Vaccine in Manitoba, Canada
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
The objective of this study is to examine the safety of the H1N1 vaccine administered in Manitoba during the second wave of the pandemic (Oct 2009-Mar 2010) by describing the age sex specific and age standardized incidence rates of certain vaccination adverse events in the vaccinated populations during the first 6 months of follow-up and to compare the rates with those in the non-vaccinated population and the general Manitoba population.
Study design The proposed study will be a retrospective analysis of population based cohorts of subjects whose vaccination status and health events before and after H1N1 vaccination are recorded in various Manitoba databases. All H1N1 vaccinated and unvaccinated individuals are eligible to be included in the study population. There will be no exclusion criteria. The list of specific adverse events of special interest (AESIs) includes: anaphylaxis, Bell's palsy, convulsions, demyelination, encephalitis, Guillain-Barré syndrome, neuritis, vasculitis and various pregnancy outcomes.
Vaccinated individuals will be identified using the Manitoba Immunization Monitoring System (MIMS). Unvaccinated individuals will be identified using the Population Registry. AESIs and other clinically relevant information will be determined using hospital, physician claim and DPIN databases.
The primary statistical analysis will be a comparison of the overall and age specific rates of deaths and AESIs in the vaccinated cohort relative to the non-vaccinated cohort. The two cohorts will be matched on age (month and year of birth), sex and postal code of residence. The analyses will be stratified by specific subgroups: (e.g. pregnant women, persons who are immune suppressed or with autoimmune disorders).
The observed number of events will be determined from the date of first vaccination for each subject and the matched control until the first occurrence of a specific event. Information on events for each person will be derived from the medical claims and hospitalization databases. The person years at risk will be calculated from the date of first vaccination until the first occurrence of the specific event, emigration from Manitoba, or until 6 months after vaccination. Incidence rate ratios and 95% confidence intervals will be calculated by comparing the standardized incidence rates in the vaccinated cohort with those in the matched non vaccinated cohort.
In addition, the observed number of deaths and AESIs in the total vaccinated population and in specific subgroups (as above) will be compared to the expected numbers based on the age sex specific rates in the general Manitoba population. Similar to the matched cohort component, the observed number of events will be determined for the vaccinated individuals from the date of first vaccination until the first occurrence of a specific event, and the person years at risk will be calculated from the date of first vaccination until the first occurrence of the specific event, emigration from Manitoba, or until 6 months after vaccination. The background rate of targeted events will be calculated utilizing information from the mortality, physician claims and hospitalization databases for the total population in Manitoba for the period 2004 2008. Since the risk of some of the events is low, calculating the age sex specific rates based on five years of data will increase the stability of the rates. The expected number of events will be calculated by multiplying the person years at risk by the age sex specific background rate of each targeted event. Standardized incidence ratios (SIRs) or mortality ratios (SMRs) will be calculated as the number of observed events over the number of expected events, with 95% confidence intervals. To assess the absolute burden of an eventual excess in observed number of events the absolute difference between the observed and expected number of events for certain AESIs will also be calculated.
Undersøgelsestype
Tilmelding (Forventet)
Kontakter og lokationer
Studiesteder
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3B 3P5
- International Centre for Infectious Diseases
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- All 6-month or older Manitoba residents are eligible
Exclusion Criteria:
- None
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
---|
Matched cohorts - population based
Two cohorts: vaccinated individuals are matched to unvaccinated individuals on the basis of age, sex, and postal code of residence.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Adverse Effects of H1N1 vaccination
Tidsramme: One year
|
Incidence rate ratios of certain vaccination adverse effects
|
One year
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Incidence Ratios of Adverse Effects
Tidsramme: One year
|
Standardized incidence ratios of certain adverse events in relation to history of H1N1 vaccination.
|
One year
|
Sex-specific adverse effects of vaccination
Tidsramme: One year
|
Determination of sex-specific adverse effects following H1N1 vaccination.
|
One year
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Salah Mahmud, M.D., Ph.D., University of Manitoba
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ICID-2011-H1N1-01
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med H1N1 influenza
-
Butantan InstituteUniversity of Sao Paulo; Insituto Adolfo Lutz; Centro de Referencia e Treinamento...AfsluttetImmunkompromitterede patienter | Sikkerhed ved pandemisk influenza A (H1N1) vaccine | Immunogenicitet af pandemisk influenza A (H1N1) vaccineBrasilien
-
Canadian Critical Care Trials GroupCanadian Institutes of Health Research (CIHR); The Physicians' Services... og andre samarbejdspartnereAfsluttet
-
Fraunhofer, Center for Molecular BiotechnologyWalter Reed Army Institute of Research (WRAIR); Defense Advanced Research...Afsluttet
-
PHAC/CIHR Influenza Research NetworkGlaxoSmithKline; CHU de Quebec-Universite Laval; The Ottawa Hospital; Hamilton... og andre samarbejdspartnereAfsluttetNy influenza A/H1N1
-
Virginia Commonwealth UniversityAfsluttetSæsonbestemt influenza | H1N1 influenzaForenede Stater
-
The University Clinic of Pulmonary and Allergic...Afsluttet
-
Hadassah Medical OrganizationUkendt
-
Seoul National University HospitalUkendtH1N1 influenzaKorea, Republikken
-
National Institute of Allergy and Infectious Diseases...AfsluttetInfluenza | Fugleinfluenza | H1N1 influenzaForenede Stater
-
Emergent BioSolutionsAfsluttetInfluenza A H3N2 | Influenza A H1N1Forenede Stater, Spanien, Canada, Puerto Rico